Related Experiment Videos

Atorvastatin exerts its anti-atherosclerotic effects by targeting the receptor for advanced glycation end products

Bo Feng1, Lei Xu, Hua Wang

  • 1Department of Endocrinology, The Affiliated East Hospital, Tongji University, Shanghai, PR China. fengbo@medmail.com.cn

Biochimica Et Biophysica Acta
|June 10, 2011
PubMed

Insights

Atorvastatin reduces cardiovascular risk by targeting the receptor for advanced glycation end products (RAGE). This study shows atorvastatin inhibits RAGE and monocyte chemoattractant protein-1 (MCP-1) expression, offering a novel mechanism for its cardioprotective effects.

Area of Science:

  • Cardiovascular Pharmacology
  • Molecular Biology
  • Endocrinology

Background:

  • Diabetes mellitus and metabolic syndrome increase cardiovascular disease risk.
  • Atorvastatin is known to reduce cardiovascular morbidity and mortality.
  • The precise mechanisms of atorvastatin's anti-atherosclerotic effects require further elucidation.

Purpose of the Study:

  • To investigate the anti-atherosclerotic mechanisms of atorvastatin.
  • To examine the role of the receptor for advanced glycation end products (RAGE) and monocyte chemoattractant protein-1 (MCP-1) in atorvastatin's action.
  • To determine if atorvastatin modulates the AGE/RAGE system.

Main Methods:

  • Real-time PCR was used to measure RAGE and MCP-1 gene expression.
  • In vitro studies exposed human umbilical vein endothelial cells to high glucose or AGEs.
  • In vivo studies used diabetic Goto Kakisaki rats fed a high-fat diet, treated with atorvastatin.

Main Results:

  • High glucose/AGEs induced oxidative stress and RAGE activation in endothelial cells.
  • Atorvastatin treatment restored glutathione levels and inhibited RAGE upregulation in vitro.
  • In diabetic rats, atorvastatin significantly downregulated aortic RAGE and MCP-1 expression, with a positive correlation between them.

Conclusions:

  • Atorvastatin exhibits a novel pleiotropic activity by targeting RAGE expression.
  • The study demonstrates atorvastatin's ability to inhibit the AGE/RAGE pathway.
  • These findings support atorvastatin's role in reducing cardiovascular disease risk through modulation of RAGE.

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...